Personalis (NASDAQ:PSNL) Shares Up 13.1% – Still a Buy?

Personalis, Inc. (NASDAQ:PSNL) shares traded up 13.1% on Monday . The company traded as high as $15.36 and last traded at $15.9130. 1,267,496 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 2,201,240 shares. The stock had previously closed at $14.07.

Wall Street Analyst Weigh In

A number of research firms have commented on PSNL. Morgan Stanley boosted their price target on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. BTIG Research dropped their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Finally, Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Personalis Price Performance

The company has a 50 day simple moving average of $10.37 and a 200-day simple moving average of $8.75. The firm has a market cap of $1.57 billion, a PE ratio of -14.74 and a beta of 2.24.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, sell-side analysts predict that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.15, for a total value of $1,315,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at $3,103,215.90. This trade represents a 29.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,620,618.94. This represents a 20.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 435,032 shares of company stock worth $5,599,929. 4.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its holdings in Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after acquiring an additional 2,395 shares during the period. Dynamic Technology Lab Private Ltd increased its stake in Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after purchasing an additional 33,044 shares during the period. Goldman Sachs Group Inc. increased its stake in Personalis by 55.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after purchasing an additional 101,706 shares during the period. Focus Partners Wealth bought a new stake in Personalis in the first quarter valued at approximately $47,000. Finally, JPMorgan Chase & Co. lifted its position in Personalis by 505.6% in the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock valued at $193,000 after purchasing an additional 24,621 shares during the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.